Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Ireland

European Innovation Council · Running

CB24 Development of a natural therapeutic treatment for late-stage lung cancer patients

Coordinator
Celtic Biotech Ltd, Ireland
Runs
1 October 2023 to 31 July 2026
Status
Running
EU funding
€2.5m
Total cost
€3.9m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190166095

What the project is doing

In the project's own words, from its summary on CORDIS.

Celtic Biotech Ireland has developed CB24(Crotoxin). A naturally derived receptor binding protein, delivered as monotherapy at home using infusion pumps, is hailed as a life changing treatment of Non-Small Cell Lung Cancer (NSCLC). Delivered intravenously, CB24 induces predictable and consistent apoptosis (cell death) and autophagy (degradation) in human lung carcinoma cells. CB24 outclass the competitive NSCLC treatment solutions (surgery, chemotherapy, and radiotherapy) through its efficacy, safety, minimal side-effects, easy to use home based treatment and suitability for all patients including those at stage 3 & 4.Celtic have already proven the efficacy of CB24 through pre-clinical and FIH clinical trials.

Through the proposed 24months EIC project, the company aims to undertake Phase I Part 3 clinical trials involving 24 patients with the ultimate goal of garnering the regulatory approvals (EMA, FDA) to market the drug as a verified cancer therapeutic.

Who is involved

OrganisationCityCountryRole
Celtic Biotech LtdDublinIrelandCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI